663 related articles for article (PubMed ID: 26946341)
21. Biophysical studies of protein misfolding and aggregation in
Sinnige T; Stroobants K; Dobson CM; Vendruscolo M
Q Rev Biophys; 2020 Jun; 49():e22. PubMed ID: 32493529
[TBL] [Abstract][Full Text] [Related]
22. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease.
Li J; Zhu M; Manning-Bog AB; Di Monte DA; Fink AL
FASEB J; 2004 Jun; 18(9):962-4. PubMed ID: 15059976
[TBL] [Abstract][Full Text] [Related]
23. Amyloids on Membrane Interfaces: Implications for Neurodegeneration.
Mahakud AK; Shaikh J; Rifa Iqbal VV; Gupta A; Tiwari A; Saleem M
J Membr Biol; 2022 Dec; 255(6):705-722. PubMed ID: 35670831
[TBL] [Abstract][Full Text] [Related]
24. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
Krüger R; Müller T; Riess O
J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401
[TBL] [Abstract][Full Text] [Related]
25. AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer's and Parkinson's Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery.
Di Scala C; Armstrong N; Chahinian H; Chabrière E; Fantini J; Yahi N
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362170
[TBL] [Abstract][Full Text] [Related]
26. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.
Windisch M; Hutter-Paier B; Rockenstein E; Hashimoto M; Mallory M; Masliah E
J Mol Neurosci; 2002; 19(1-2):63-9. PubMed ID: 12212795
[TBL] [Abstract][Full Text] [Related]
27. Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases.
Tabner BJ; Turnbull S; El-Agnaf O; Allsop D
Curr Top Med Chem; 2001 Dec; 1(6):507-17. PubMed ID: 11895127
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
Beal MF
J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
[TBL] [Abstract][Full Text] [Related]
29. Age-dependent α-synuclein aggregation in the Microcebus murinus lemur primate.
Canron MH; Perret M; Vital A; Bézard E; Dehay B
Sci Rep; 2012; 2():910. PubMed ID: 23205271
[TBL] [Abstract][Full Text] [Related]
30. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
31. Mangosteen Pericarp and Its Bioactive Xanthones: Potential Therapeutic Value in Alzheimer's Disease, Parkinson's Disease, and Depression with Pharmacokinetic and Safety Profiles.
Do HTT; Cho J
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867357
[TBL] [Abstract][Full Text] [Related]
32. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
Belaidi AA; Bush AI
J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340
[TBL] [Abstract][Full Text] [Related]
33. [The role of proteins in neurodegenerative disease].
Szwed A; Miłowska K
Postepy Hig Med Dosw (Online); 2012 Apr; 66():187-95. PubMed ID: 22706103
[TBL] [Abstract][Full Text] [Related]
34. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
[TBL] [Abstract][Full Text] [Related]
35. Alternative platelet activation pathways and their role in neurodegenerative diseases.
Ferrer-Raventós P; Beyer K
Neurobiol Dis; 2021 Nov; 159():105512. PubMed ID: 34537329
[TBL] [Abstract][Full Text] [Related]
36. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases.
Irvine GB; El-Agnaf OM; Shankar GM; Walsh DM
Mol Med; 2008; 14(7-8):451-64. PubMed ID: 18368143
[TBL] [Abstract][Full Text] [Related]
37. A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.
Joshi P; Chia S; Habchi J; Knowles TP; Dobson CM; Vendruscolo M
ACS Comb Sci; 2016 Mar; 18(3):144-53. PubMed ID: 26923286
[TBL] [Abstract][Full Text] [Related]
38. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease.
Ganguly G; Chakrabarti S; Chatterjee U; Saso L
Drug Des Devel Ther; 2017; 11():797-810. PubMed ID: 28352155
[TBL] [Abstract][Full Text] [Related]
39. Role of mtDNA disturbances in the pathogenesis of Alzheimer's and Parkinson's disease.
Antonyová V; Kejík Z; Brogyányi T; Kaplánek R; Pajková M; Talianová V; Hromádka R; Masařík M; Sýkora D; Mikšátková L; Martásek P; Jakubek M
DNA Repair (Amst); 2020; 91-92():102871. PubMed ID: 32502755
[TBL] [Abstract][Full Text] [Related]
40. Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases.
Braak H; Del Tredici K
Cold Spring Harb Perspect Biol; 2016 Nov; 8(11):. PubMed ID: 27580631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
